Epigenomics receives €2.8m grant to validate lung cancer biomarkers in blood plasma
Goal is to develop a CE-marked product for the detection of lung cancer in blood plasma under the new in-vitro diagnostic directive
Epigenomics will receive an EU grant from Horizon 2020, the industrial leadership research and innovation programme for SME (small and medium-sized enterprises). The grant duration is expected to be 24 months with a total fund volume of up to €2.77m.
The money will fund the clinical research to validate Epigenomics' proprietary lung cancer biomarkers with the goal of developing a CE-marked product for the detection of lung cancer in blood plasma under the new in-vitro diagnostic directive.
'With our Epi proLung test, we have already proven that new and innovative diagnostic tests can make a difference in the detection of lung cancer,' said Dr Uwe Staub, COO of Epigenomics. 'With this new project, we will clinically validate a novel CE-marked diagnostic product that can detect lung cancer in blood plasma at an early stage and has a variety of possible future clinical applications in the diagnosis of lung cancer.'
The EU Commission informed Epigenomics that the grant proposal has been favourably evaluated and that the agency wishes to proceed with the grant agreement. In a next step, the grant agreement preparation and the internal completion of the formal selection process will be concluded.
